Inovio Pharmaceuticals, Inc. (INO) Financial Ratios
27 years of historical data (1999–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.03
↓-100% vs avg
5yr avg: 7.15
30Y Low0.0·High121.3
ROE
↓
-703.1%
↑-232% vs avg
5yr avg: -211.7%
30Y Low-258%·High-20%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
INO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Inovio Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $642M | $816M | $50M | $136M | $372M | $12.9B | $18.0B | $4.9B | $4.4B | $4.1B | $6.1B |
| Enterprise Value | $-34263149320 | $-34089669640 | $-4243731 | $152M | $358M | $12.8B | $17.8B | $5.0B | $4.4B | $4.0B | $6.1B |
| P/E Ratio → | -0.76 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 228.26 | 163.10 | 36.27 | 7241.33 | 2434.12 | 1200.19 | 145.72 | 96.16 | 172.39 |
| P/B Ratio | 0.03 | 0.03 | 0.73 | 1.16 | 1.67 | 32.16 | 39.12 | 913.07 | 51.04 | 28.49 | 49.42 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
INO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | -19.49 | 182.21 | 34.88 | 7219.85 | 2405.55 | 1218.99 | 144.95 | 95.60 | 171.85 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
INO Profitability
Margins and return-on-capital ratios measuring operating efficiency
Operating margins have compressed from -17300.3% to -51616.9% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -703.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | — | — | -51616.9% | -17300.3% | -2607.4% | -16972.3% | -1674.2% | -2702.1% | -308.7% | -198.1% | -215.5% |
| Net Profit Margin | — | — | -49254.3% | -16239.9% | -2726.7% | -17109.9% | -2245.4% | -2902.8% | -318.1% | -208.9% | -208.5% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -703.1% | -703.1% | -115.4% | -79.5% | -90.0% | -70.6% | -71.3% | -258.2% | -84.5% | -66.4% | -49.3% |
| ROA | -228.3% | -228.3% | -75.5% | -52.0% | -66.3% | -58.6% | -48.7% | -86.8% | -60.9% | -48.9% | -38.1% |
| ROIC | — | — | -114.1% | -63.3% | -70.5% | -73.9% | -56.0% | -114.1% | -77.5% | -56.3% | -51.4% |
| ROCE | -565.3% | -565.3% | -109.0% | -75.7% | -78.5% | -64.9% | -40.7% | -107.0% | -76.0% | -59.4% | -48.8% |
INO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $44.3B exceeds total debt of $9.4B, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.39 | 0.39 | 0.17 | 0.26 | 0.14 | 0.08 | 0.08 | 18.41 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.45 | -0.79 | 0.14 | -0.06 | -0.10 | -0.46 | 14.30 | -0.27 | -0.17 | -0.16 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -632.05 | -117.71 | -213.38 | -155.55 | -14.26 | -13.98 | — | -3225.35 | -547.48 |
Net cash position: cash ($44.3B) exceeds total debt ($9.4B)
INO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.40x means Inovio Pharmaceuticals, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 3.60x to 1.40x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.40 | 1.40 | 2.77 | 3.60 | 3.25 | 6.82 | 11.30 | 2.94 | 2.49 | 3.91 | 2.84 |
| Quick Ratio | 1.40 | 1.40 | 2.77 | 3.60 | 3.25 | 6.82 | 11.30 | 2.94 | 2.49 | 3.91 | 2.84 |
| Cash Ratio | 1.34 | 1.34 | 2.66 | 3.41 | 2.61 | 6.10 | 9.87 | 2.80 | 2.30 | 3.60 | 2.39 |
| Asset Turnover | — | — | 0.00 | 0.00 | 0.03 | 0.00 | 0.01 | 0.03 | 0.23 | 0.23 | 0.20 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 2009.84 | 1055.17 | 417.50 | 1651.88 | 938.88 | 180.38 | 48.56 | 56.11 | 171.00 |
INO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Inovio Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $469M | $27M | $22M | $20M | $215M | $170M | $125M | $93M | $82M | $73M |
Peer Comparison
Compare INO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 INOYou | $642M | -0.8 | — | — | — | — | -703.1% | — | — |
 NVAX | $2B | 3.6 | 2.6 | — | 93.7% | 50.1% | — | — | 0.4 |
 OCGN | $487M | -6.3 | — | — | 45.9% | -1425.7% | -776.9% | -1565.6% | — |
 DVAX | $2B | 77.5 | 503.2 | 30.2 | 82.2% | -1.5% | 4.5% | -0.4% | 64.7 |
 VXRT | $178M | 10.6 | 7.4 | 23.5 | — | 7.6% | 22.3% | 27.1% | 0.5 |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 MRNA | $19B | -6.7 | — | — | 55.3% | -158.1% | -28.9% | -26.1% | — |
 BNTX | $24B | -17.6 | — | 74.3 | 77.6% | -22.6% | -5.7% | -4.3% | — |
 ARCT | $253M | -3.7 | — | — | 95.5% | -111.5% | -28.9% | -277.1% | — |
 GILD | $166B | 19.8 | 17.0 | 17.6 | 86.7% | 40.1% | 40.7% | 23.4% | 2.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 27 years · Updated daily
See INO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare INO vs NVAX
Side-by-side business, growth, and profitability comparison vs Novavax, Inc..
Start ComparisonINO — Frequently Asked Questions
Quick answers to the most common questions about buying INO stock.
What is Inovio Pharmaceuticals, Inc.'s P/E ratio?
Inovio Pharmaceuticals, Inc.'s current P/E ratio is -0.8x. This places it at the 50th percentile of its historical range.
What is Inovio Pharmaceuticals, Inc.'s ROE?
Inovio Pharmaceuticals, Inc.'s return on equity (ROE) is -703.1%. The historical average is -77.7%.
Is INO stock overvalued?
Based on historical data, Inovio Pharmaceuticals, Inc. is trading at a P/E of -0.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.